Relmada Therapeutics (RLMD) Tops Q2 EPS by 6c
Tweet
Share
E-mail
Get Alerts RLMD Hot Sheet
Join SI Premium – FREE
Relmada Therapeutics (NASDAQ: RLMD) reported Q2 EPS of ($0.84), $0.06 better than the analyst estimate of ($0.90).
For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AngioDynamics (ANGO) Tops Q4 EPS by 2c ; Offers Guidance
- Fastenal (FAST) Reports In-Line Q2 EPS, Beats on Revenue
- Rosenblatt Reiterates Neutral Rating on Netflix (NFLX) Ahead of Earnings
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
